Aeterna Zentaris (NASDAQ:AEZS) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a research report sent to investors on Saturday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Stock Performance

NASDAQ:AEZS opened at $2.75 on Friday. Aeterna Zentaris has a one year low of $3.96 and a one year high of $12.00. The business’s 50-day simple moving average is $2.89 and its 200 day simple moving average is $3.32. The stock has a market cap of $4.93 million, a price-to-earnings ratio of -0.19 and a beta of 1.55.

About Aeterna Zentaris

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.